VAGINAL BROMOCRIPTINE - CLINICAL AND BIOCHEMICAL EFFECTS

被引：14

作者：

GINSBURG, J

HARDIMAN, P

THOMAS, M

机构：

[1] Department of Endocrinology, Royal Free Hospital, School of Medicine, London

[2] Department of Chemical Pathology, Royal Free Hospital, School of Medicine, London

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 02期

关键词：

VAGINAL BROMOCRIPTINE; HYPERPROLACTINEMIA; NORMOPROLACTINEMIA;

D O I：

10.3109/09513599209046395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Adverse effects occur in over 50% of women taking oral bromocriptine, causing at least 10% to discontinue treatment. Although the drug is absorbed from the vagina and reportedly caused no side-effects in one patient intolerant of oral bromocriptine, long-term clinical effects of daily vaginal administration have not been assessed. We have now given bromocriptine vaginally for up to 2 years to 31 hyperprolactinemic and five normoprolactinemic women, 17 of whom were intolerant of oral bromocriptine. The drug was well absorbed from the vagina and a daily dosage of 2.5 mg lowered serum prolactin levels in 28 of the hyperprolactinemic women (in 11 to within normal limits), restored menstrual cyclicity, and abolished galactorrhea; one of the four infertile women conceived. Minor side-effects occurred in only three women. Vaginal administration is clinically effective, avoids the adverse effects of oral therapy and could be the first-line treatment for patients requiring bromocriptine.

引用

页码：119 / 126

页数：8

共 18 条

[1]

Varga L., Lutterbeck P.M., Pryor J.S., Wenner R., Erb H., Suppression of puerperal lactation with an ergot alkaloid. A double blind study, Br. Med.J., 2, pp. 743-744, (1972)

[2]

Besser G.M., Parkes L., Edwards C.R.W., Forsyth I.A., McNeiUy A.S., Galactorrhoea: successful treatment with reduction of plasma prolactin levels by bromoergocriptine, Br. Med. J., 3, pp. 669-672, (1972)

[3]

Thorner M.O., Besser G.M., Hagen C., Mc Neilly A.S., Long term treatment of galactorrhoea and hypogonadism with bromocriptine, Br. Med.J., 2, pp. 419-422, (1974)

[4]

Thorner M., Besser G.M., Bromocriptine treatment of hyperprolactinaemic hypogonadism, Acta Endocrinol., 88, pp. 131-146, (1978)

[5]

Parkes J.D., Bromocriptine in the treatment of Parkinsonism, Drugs, 17, pp. 365-382, (1979)

[6]

Bateman D.E., Tunbridge W.M.G., Bromocriptine in the treatment of acromegaly, Drugs, 17, pp. 359-364, (1979)

[7]

Mansel R.E., Dogliotti L., European multicentre trial of bromocriptine in cyclic mastalgia, Lancet, 335, pp. 191-193, (1990)

[8]

Andersch B., Hahn L., Wendestam C., Abrahmsonn L., Treatment of the premenstrual syndrome with bromocriptine, Acta Endocrinol., 88, pp. 165-174, (1978)

[9]

Cuellar F.G., Bromocriptine mesylate (Pardolel) in the management of amenorrhoea/galactorrhoea associated with hyperprolactinaemia, Obstet. Gynecol., 55, pp. 278-284, (1980)

[10]

LeWitt P.A., Gopinathan G., Ward C.D., Sanes J.N., Dambrosia J.M., Durso R., Canle D.B., Lisuride versus bromocriptine treatment in Parkinson's disease: a double-blind study, Neurology, 32, pp. 69-72, (1982)

← 1 2 →